118 related articles for article (PubMed ID: 1550582)
1. The specific cytotoxicity of immunoconjugates containing blocked ricin is dependent on the residual binding capacity of blocked ricin: evidence that the membrane binding and A-chain translocation activities of ricin cannot be separated.
Goldmacher VS; Lambert JM; Blättler WA
Biochem Biophys Res Commun; 1992 Mar; 183(2):758-66. PubMed ID: 1550582
[TBL] [Abstract][Full Text] [Related]
2. Blocked and non-blocked ricin immunotoxins against the CD4 antigen exhibit higher cytotoxic potency than a ricin A chain immunotoxin potentiated with ricin B chain or with a ricin B chain immunotoxin.
Wawrzynczak EJ; Watson GJ; Cumber AJ; Henry RV; Parnell GD; Rieber EP; Thorpe PE
Cancer Immunol Immunother; 1991; 32(5):289-95. PubMed ID: 1998970
[TBL] [Abstract][Full Text] [Related]
3. An immunotoxin prepared with blocked ricin: a natural plant toxin adapted for therapeutic use.
Lambert JM; Goldmacher VS; Collinson AR; Nadler LM; Blättler WA
Cancer Res; 1991 Dec; 51(23 Pt 1):6236-42. PubMed ID: 1718599
[TBL] [Abstract][Full Text] [Related]
4. Galactose-induced dimerization of blocked ricin at acidic pH: evidence for a third galactose-binding site in ricin B-chain.
Venkatesh YP; Lambert JM
Glycobiology; 1997 Apr; 7(3):329-35. PubMed ID: 9147041
[TBL] [Abstract][Full Text] [Related]
5. Blockade of the galactose-binding sites of ricin by its linkage to antibody. Specific cytotoxic effects of the conjugates.
Thorpe PE; Ross WC; Brown AN; Myers CD; Cumber AJ; Foxwell BM; Forrester JT
Eur J Biochem; 1984 Apr; 140(1):63-71. PubMed ID: 6608447
[TBL] [Abstract][Full Text] [Related]
6. The galactose-binding sites of the cytotoxic lectin ricin can be chemically blocked in high yield with reactive ligands prepared by chemical modification of glycopeptides containing triantennary N-linked oligosaccharides.
Lambert JM; McIntyre G; Gauthier MN; Zullo D; Rao V; Steeves RM; Goldmacher VS; Blättler WA
Biochemistry; 1991 Apr; 30(13):3234-47. PubMed ID: 1706936
[TBL] [Abstract][Full Text] [Related]
7. Novel synthesis and in vitro characterization of disulfide-linked ricin-monoclonal antibody conjugates devoid of galactose binding activity.
Pietersz GA; Kanellos J; McKenzie IF
Cancer Res; 1988 Aug; 48(16):4469-76. PubMed ID: 3260814
[TBL] [Abstract][Full Text] [Related]
8. Identification and characterization of a monoclonal antibody recognizing a galactose-binding domain of the toxin ricin.
Colombatti M; Johnson VG; Skopicki HA; Fendley B; Lewis MS; Youle RJ
J Immunol; 1987 May; 138(10):3339-44. PubMed ID: 2437188
[TBL] [Abstract][Full Text] [Related]
9. Cell surface and intracellular functions for ricin galactose binding.
Newton DL; Wales R; Richardson PT; Walbridge S; Saxena SK; Ackerman EJ; Roberts LM; Lord JM; Youle RJ
J Biol Chem; 1992 Jun; 267(17):11917-22. PubMed ID: 1601861
[TBL] [Abstract][Full Text] [Related]
10. Modification of the binding site(s) of lectins by an affinity column carrying an activated galactose-terminated ligand.
Moroney SE; D'Alarcao LJ; Goldmacher VS; Lambert JM; Blättler WA
Biochemistry; 1987 Dec; 26(25):8390-8. PubMed ID: 3442663
[TBL] [Abstract][Full Text] [Related]
11. Double-lectin site ricin B chain mutants expressed in insect cells have residual galactose binding: evidence for more than two lectin sites on the ricin toxin B chain.
Fu T; Burbage C; Tagge E; Chandler J; Willingham M; Frankel A
Bioconjug Chem; 1996; 7(6):651-8. PubMed ID: 8950484
[TBL] [Abstract][Full Text] [Related]
12. Studies on the galactose-binding site of ricin and the hybrid toxin Man6P-ricin.
Youle RJ; Murray GJ; Neville DM
Cell; 1981 Feb; 23(2):551-9. PubMed ID: 7471212
[TBL] [Abstract][Full Text] [Related]
13. Ricin B chain-containing immunotoxins prepared with heat-denatured B chain lacking galactose-binding ability potentiate the cytotoxicity of a cell-reactive ricin A chain immunotoxin.
Wawrzynczak EJ; Drake AF; Watson GJ; Thorpe PE; Vitetta ES
Biochim Biophys Acta; 1988 Aug; 971(1):55-62. PubMed ID: 2841982
[TBL] [Abstract][Full Text] [Related]
14. Ricin toxin contains at least three galactose-binding sites located in B chain subdomains 1 alpha, 1 beta, and 2 gamma.
Frankel AE; Burbage C; Fu T; Tagge E; Chandler J; Willingham MC
Biochemistry; 1996 Nov; 35(47):14749-56. PubMed ID: 8942636
[TBL] [Abstract][Full Text] [Related]
15. Correlation between in vivo toxicity and preclinical in vitro parameters for the immunotoxin anti-B4-blocked ricin.
Grossbard ML; Lambert JM; Goldmacher VS; Blättler WA; Nadler LM
Cancer Res; 1992 Aug; 52(15):4200-7. PubMed ID: 1379121
[TBL] [Abstract][Full Text] [Related]
16. In vivo studies of whole ricin monoclonal antibody immunoconjugates for the treatment of murine tumours.
Kanellos J; MacKenzie IF; Pietersz GA
Immunol Cell Biol; 1988; 66 ( Pt 5-6)():403-15. PubMed ID: 3265693
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibody-ricin A chain conjugate selectively cytotoxic for cells bearing the common acute lymphoblastic leukemia antigen.
Raso V; Ritz J; Basala M; Schlossman SF
Cancer Res; 1982 Feb; 42(2):457-64. PubMed ID: 6948605
[TBL] [Abstract][Full Text] [Related]
18. Synergy between immunotoxins prepared with native ricin A chains and chemically-modified ricin B chains.
Vitetta ES
J Immunol; 1986 Mar; 136(5):1880-7. PubMed ID: 2419417
[TBL] [Abstract][Full Text] [Related]
19. Antibody-ricin conjugates: a method of linkage which blocks the galactose binding site of ricin.
Foxwell BM; Ross WC; Thorpe PE
Behring Inst Mitt; 1984 May; (74):101-7. PubMed ID: 6477350
[TBL] [Abstract][Full Text] [Related]
20. Recombinant ricin toxin A chain cytotoxicity against carcinoembryonic antigen expressing tumour cells mediated by a bispecific monoclonal antibody and its potentiation by ricin toxin B chain.
Embleton MJ; Charleston A; Robins RA; Pimm MV; Baldwin RW
Br J Cancer; 1991 May; 63(5):670-4. PubMed ID: 2039690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
